Table 4 Univariate and multivariate analyses of the overall response rate.

From: Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer

Characteristic

Best ORR (CR + PR)

P-value

Multivariate analysis

Achieved

Not achieved

OR

95% CI

 P-value

Age, years

≥60

13 (59.1)

12 (31.6)

0.037

1

 

0.016

<60

9 (40.9)

26 (68.4)

 

4.858

1.344–17.563

 

Sex

Male

12 (54.5)

21 (55.3)

0.957

   

Female

10 (45.5)

17 (44.7)

    

Disease extent

LAPC

4 (18.2)

10 (26.3)

0.542

   

MPC

18 (81.8)

28 (73.7)

    

CA 19-9, U/mL

≥37.0

16 (72.7)

31 (81.6)

0.423

   

<37.0

6 (27.3)

7 (18.4)

    

Total bilirubin, mg/dL

>1.2

5 (22.7)

7 (18.4)

0.688

   

≤1.2

17 (77.3)

31 (81.6)

    

Albumin, g/dL

≥3.3

21 (95.5)

36 (94.7)

1.000

   

<3.3

1 (4.5)

2 (5.3)

    

sPD-L1, ng/mL

≥4.6

3 (13.6)

5 (13.2)

1.000

   

<4.6

19 (86.4)

33 (86.8)

    

Δ sPD-L1, ng/mL

≥0

5 (26.3)

19 (55.9)

0.038

4.267

1.123–16.212

0.033

(response-initial)

<0

14 (73.7)

15 (44.1)

 

1

  

NLR

≥1.83

16 (72.7)

30 (78.9)

0.583

   

<1.83

6 (27.3)

8 (21.1)

    

PLR

≥109.6

16 (72.7)

27 (71.1)

0.890

   

<109.6

6 (27.3)

11 (28.9)

    
  1. Abbreviations: ORR = overall response rate; CR = complete response; PR = partial response; LAPC = locally advanced pancreatic cancer; MPC = metastatic pancreatic cancer; CA 19-9 = cancer antigen 19-9; sPD-L1 = soluble programmed death-ligand 1; Δ sPD-L1 = the difference in sPD-L1 levels between the first response assessment time point and time of initial diagnosis with unresectable pancreatic cancer; NLR = neutrophil-to-lymphocyte ratio; PLR = platelet-to-lymphocyte ratio; OR = odd ratio; and CI = confidence interval.
Back to article page